Clinical Trial Update: A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating the combination of Serplulimab (HLX10) with Bevacizumab (HLX04) and XELOX chemotherapy in patients with metastatic colorec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (HLX04) (bevacizumab)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• Serplulimab (HLX10) (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Metastatic Colorectal Cancer | Phase 2, Phase 3 | Status: RECRUITING